Evidence map›Paper›PMID 40419510›Full record

ArticleScientific reports2025

Integrating machine learning and multi-omics analysis to unveil key programmed cell death patterns and immunotherapy targets in kidney renal clear cell carcinoma.

Fanyan Ou, Yi Pan, Qiuli Chen, Lixiong Zeng, Kanglai Wei, Delin Liu, Qian Guo, Liquan Zhou, Jie Yang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fanyan Ou *Department of Clinical Pathology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yi Pan *Department of Urology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Qiuli Chen *Department of Clinical Pathology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lixiong ZengDepartment of Clinical Pathology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Kanglai WeiDepartment of Clinical Pathology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Delin LiuDepartment of Clinical Pathology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Qian GuoDepartment of General Practice, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. guoqian990515@163.com.
Liquan ZhouDepartment of Urology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. zlqdr1972@163.com.
Jie YangClinical Medical Research Center, the Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, Guangxi, China. shenggj1992@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney renal clear cell carcinoma (KIRC), a cancer characterized by substantial immune infiltration, exhibits limited sensitivity to conventional radiochemotherapy. Although immunotherapy has shown efficacy in some patients, its applicability is not universally effective. Studies have indicated that programmed cell death (PCD) can modulate the activity of immune cells and participate in the regulation of antitumor immune responses. However, systematic research on how various PCD patterns in KIRC affect the responsiveness to immunotherapy is lacking and requires in-depth investigation. We utilized a combination of 101 machine learning algorithms to analyze the TCGA-KIRC cohort and the GSE22541 KIRC patients, screening for cell death patterns closely associated with prognosis from 18 potential modes. Integrating multi-omics analysis, including immune cell infiltration, phenotyping, functional analysis, immune checkpoint exploration, and gene set enrichment analysis (GSEA), we explored the relationship between key cell death patterns and patients' responses to immunotherapy. Finally, potential drug targets were identified through drug sensitivity screening and molecular docking techniques. Our sophisticated risk assessment model successfully identified two PCD patterns, Anoikis and lysosome-dependent cell death (LDCD), closely associated with the prognosis of KIRC patients, with the high-risk group exhibiting poor outcomes. Immune cell analysis revealed upregulated expression of T follicular helper (Tfh) cells in both PCD patterns. Analysis of immune checkpoints disclosed enhanced expression of human leukocyte antigen E (HLA-E) across both patterns. Frequent mutations in the TTN and MUC16 genes were observed in the Anoikis pattern, whereas in the LDCD pattern, although the high-risk group had a higher mutation rate, there was no significant difference in tumor mutational burden. GSEA analysis indicated significant enrichment of the primary immunodeficiency pathway in the Anoikis high-risk group and significant enrichment of the spliceosomal tri-snrnp complex assembly pathway in the LDCD high-risk group. Drug sensitivity analysis showed notable sensitivity to SB505124 in both PCD patterns. HMOX1 and PIK3CG were identified as common genes in the two key PCD patterns, and molecular docking analysis confirmed stable binding affinity between Carnosol and HMOX1, and between PROTAC and PIK3CG. Our study identifies Anoikis and LDCD as prognostic PCD patterns in KIRC, with key immune cells, genetic mutations, and drug sensitivity profiles. HMOX1 and PIK3CG are common genes with stable binding to Carnosol and PROTAC, respectively, while SB505124 shows significant sensitivity to both PCD modes, suggesting potential therapeutic targets.

Indexed as

ApoptosisCarcinoma, Renal CellImmunotherapyKidney NeoplasmsMachine LearningAnoikisGene Expression Regulation, NeoplasticHumansMolecular Docking SimulationMultiomicsPrognosisImmune checkpointsKIRCMachine learning algorithmsProgrammed cell death

Identifiers

PMID40419510
PMCPMC12106685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.